Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of VIR-2218 and VIR-3434 in Hepatic Impairment
NCT05484206Phase 1Completed
- Sponsor
- Vir Biotechnology
- Start
- Sep 2022
- Primary completion
- Dec 2025
- Modality
- Conjugated siRNA, Monoclonal Antibodies, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of elebsiran and tobevibart in hepatitis B (HBV) (9 cohorts), sponsored by Vir Biotechnology. Primary endpoints: Maximum observed Plasma concentration at 5 days, Area Under The Plasma Concentration-time Curve from Time Zero to Time of Last Quantifiable Concentration at 5 days and 1 more. Started Sep 2022; status: completed.
02
Drugs
elebsirantobevibart
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05484206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05484206.